| dc.contributor.author | Hawkins, Naomi | |
| dc.date.accessioned | 2016-01-07T08:49:49Z | |
| dc.date.issued | 2016 | |
| dc.description.abstract | Recent legal developments have reinvigorated the debate around the patenting of human genetic sequences. These cases have been predicated on an assumption that overturning patents on human genes will address a major flaw in the patent system, and that invalidating the patents will solve a serious problem. However, these changes to the law do not adequately address the underlying objections to patenting life and concerns for patient access, and will not ‘solve’ the problem. Instead, a focus on the patentability of DNA alone has to some extent obscured other solutions already existing in patent law, or which could be introduced. | en_GB |
| dc.description.sponsorship | Economic and Social Research Council (ESRC) | en_GB |
| dc.description.sponsorship | Wellcome Trust | en_GB |
| dc.identifier.citation | Vol 38(2), pp. 83-91 | |
| dc.identifier.grantnumber | ES/K009575/1 | en_GB |
| dc.identifier.grantnumber | WT077869/Z/05/Z | en_GB |
| dc.identifier.uri | http://hdl.handle.net/10871/19146 | |
| dc.language.iso | en | en_GB |
| dc.publisher | Sweet and Maxwell | en_GB |
| dc.rights.embargoreason | Publisher agreement for 6 month embargo | |
| dc.title | A red herring – Invalidity of human gene sequence patents | en_GB |
| dc.type | Article | en_GB |
| dc.identifier.issn | 0142-0461 | |
| dc.identifier.journal | European Intellectual Property Review | en_GB |
| refterms.dateFOA | 2016-07-31T23:00:00Z | |
